Date Filed | Type | Description |
08/10/2023 |
4
| Hamdy Ahmed MD (See Remarks) has filed a Form 4 on Vincerx Pharma, Inc.
Txns:
| Bought 16,900 shares
@ $0.9464, valued at
$16k
Bought 5,400 shares
@ $0.9569, valued at
$5.2k
|
|
12/14/2022 |
4
| Hamdy Ahmed MD (CEO) has filed a Form 4 on Vincerx Pharma, Inc.
Txns:
| Bought 35,280 shares
@ $0.8656, valued at
$30.5k
|
|
08/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/27/2021 |
4
| Hamdy Ahmed MD (CEO) has filed a Form 4 on Vincerx Pharma, Inc.
Txns:
| Bought 6,450 shares
@ $10.0232, valued at
$64.6k
|
|
06/30/2021 |
4
| Hamdy Ahmed MD (CEO) has filed a Form 4 on Vincerx Pharma, Inc.
Txns:
| Bought 7,830 shares
@ $12.77, valued at
$100k
|
|
12/30/2020 |
SC 13D
| Hamdy Ahmed MD reports a 21.5% stake in Vincera Pharma, Inc. |
12/28/2020 |
4
| Hamdy Ahmed MD (President and CEO) has filed a Form 4 on Vincera Pharma, Inc.
Txns:
| Granted 1,618,199 shares
@ $0 |
|
12/28/2020 |
3
| Hamdy Ahmed MD (President and CEO) has filed a Form 3 on Vincera Pharma, Inc. |
05/03/2011 |
4
| Hamdy Ahmed MD (Chief Medical Officer) has filed a Form 4 on PHARMACYCLICS INC
Txns:
| Acquired 5,011 shares
@ $1.6065, valued at
$8.1k
|
|
11/02/2010 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
10/15/2010 |
4
| Hamdy Ahmed MD (Chief Medical Officer) has filed a Form 4 on PHARMACYCLICS INC
Txns:
| Granted 30,000 options to buy
@ $7.69, valued at
$230.7k
|
|
10/07/2010 |
4
| Hamdy Ahmed MD (Chief Medical Officer) has filed a Form 4 on PHARMACYCLICS INC
Txns:
| Sold 15,000 shares
@ $8.2, valued at
$123k
Exercised 15,000 options to buy
@ $0.73, valued at
$11k
|
|
04/13/2010 |
4
| Hamdy Ahmed MD (Chief Medical Officer) has filed a Form 4 on PHARMACYCLICS INC
Txns:
| Granted 30,000 options to buy
@ $7.19, valued at
$215.7k
|
|
11/03/2009 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |